Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also stave off dementia?

Now, a new study published in JAMA Network Open suggests that for people with obesity and type 2 diabetes, these drugs—known as GLP-1 receptor agonists —may also reduce the risk of death and lower the ...

FAT jabs are better than widely prescribed metformin when it comes to curbing dementia risk in people with type 2 diabetes, ...

The popular diabetes and weight-loss drug semaglutide may lower the risk of dementia when taken by Type 2 diabetes patients, new research from the Case Western Reserve School of Medicine suggests.

A recent study revealed that weight loss drugs, GLP-1s, including Ozempic and Zepbound, may help in treating several chronic ...

A new study found that semaglutides like Ozempic are linked to a lower risk of Alzheimer's disease and dementia. Below, a neurologist explains the connection.

THEY’VE been hailed as miracle weight-loss jabs – but the effects of Ozempic-style drugs could go far beyond the waistline. New research suggests these so-called “skinny pens” may also ...

Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

Ozempic use is associated with a lowered risk for cognitive problems, researchers in a new study said. The findings, however, cannot be applied to users who do not have diabetes. The study ...

Ozempic linked to lower dementia rate in Oxford study After a year on the drug, patients had a 48% lower risk of dementia compared with those who’d taken sitagliptin.

Ozempic may lower dementia and nicotine dependence risk in people with type 2 diabetes. A recent study shows fewer cognitive deficits and lower smoking rates compared with other diabetes drugs.

Novo Nordisk A/S’s Ozempic was linked to lower rates of dementia and a range of other mental problems in a University of Oxford study that raises expectations about the diabetes drug’s ...